Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ye, Byong Duk | - |
dc.contributor.author | Pesegova, Marina | - |
dc.contributor.author | Alexeeva, Olga | - |
dc.contributor.author | Osipenko, Marina | - |
dc.contributor.author | Lahat, Adi | - |
dc.contributor.author | Dorofeyev, Andriy | - |
dc.contributor.author | Fishman, Sigal | - |
dc.contributor.author | Levchenko, Olena | - |
dc.contributor.author | Cheon, Jae Hee | - |
dc.contributor.author | Scribano, Maria Lia | - |
dc.contributor.author | Mateescu, Radu-Bogdan | - |
dc.contributor.author | Lee, Kang-Moon | - |
dc.contributor.author | Eun, Chang Soo | - |
dc.contributor.author | Lee, SangJoon | - |
dc.contributor.author | Lee, Sung Young | - |
dc.contributor.author | Kim, HoUng | - |
dc.contributor.author | Schreiber, Stefan | - |
dc.contributor.author | Fowler, Heather | - |
dc.contributor.author | Cheung, Raymond | - |
dc.contributor.author | Kim, Young-Ho | - |
dc.date.accessioned | 2021-08-02T11:54:06Z | - |
dc.date.available | 2021-08-02T11:54:06Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 0140-6736 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/14292 | - |
dc.description.abstract | Background The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indication extrapolation have been expressed. This study investigated whether CT-P13 is non-inferior to infliximab in patients with Crohn's disease who were naive to biological therapy. Methods In this randomised, multicentre, double-blind, phase 3 non-inferiority study, we enrolled patients with active Crohn's disease who had not responded to, or were intolerant to, non-biological treatments. Patients were randomly assigned (1:1:1:1) to receive CT-P13 then CT-P13, CT-P13 then infliximab, infliximab then infliximab, or infliximab then CT-P13, with switching occurring at week 30. Patients received 5 mg/kg CT-P13 or infliximab at weeks 0, 2, 6, and then every 8 weeks up to week 54. The primary endpoint was the proportion of patients with a decrease of 70 points or more in Crohn's Disease Activity Index (CDAI) from baseline to week 6. A non-inferiority margin of −20% was set (CT-P13 was non-inferior to infliximab if the lower limit of the two-sided 95% CI for the treatment difference was greater than −20). This trial is registered with ClinicalTrials.gov, number NCT02096861, and is completed. Findings Between Aug 20, 2014, and Feb 15, 2017, 308 patients were assessed for eligibility, and 220 patients were enrolled: 111 were randomly assigned to initiate CT-P13 (56 to the CT-P13–CT-P13 group and 55 to the CT-P13–infliximab group) and 109 to initiate infliximab (54 to the infliximab–infliximab group and 55 to the infliximab–CT-P13 group). CDAI-70 response rates at week 6 were similar for CT-P13 (77 [69·4%, 95% CI 59·9 to 77·8] of 111) and infliximab (81 [74·3%, 95% CI 65·1 to 82·2] of 109; difference −4·9% [95% CI −16·9 to 7·3]), thereby establishing non-inferiority. Over the total study period, 147 (67%) patients experienced at least one treatment-emergent adverse event (36 [64%] in the CT-P13–CT-P13 group, 34 [62%] in the CT-P13–infliximab group, 37 [69%] in the infliximab–infliximab group, and 40 [73%] in the infliximab–CT-P13 group). Interpretation This study showed non-inferiority of CT-P13 to infliximab in patients with active Crohn's disease. Biosimilar CT-P13 could be a new option for the treatment of active Crohn's disease. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Eun, Chang Soo | - |
dc.identifier.doi | 10.1016/S0140-6736(18)32196-2 | - |
dc.identifier.scopusid | 2-s2.0-85064589346 | - |
dc.identifier.wosid | 000466244500028 | - |
dc.identifier.bibliographicCitation | LANCET, v.393, no.10182, pp.1699 - 1707 | - |
dc.relation.isPartOf | LANCET | - |
dc.citation.title | LANCET | - |
dc.citation.volume | 393 | - |
dc.citation.number | 10182 | - |
dc.citation.startPage | 1699 | - |
dc.citation.endPage | 1707 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | REPORTED OUTCOME MEASURES | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | INNOVATOR INFLIXIMAB | - |
dc.subject.keywordPlus | PARALLEL-GROUP | - |
dc.subject.keywordPlus | ACTIVITY INDEX | - |
dc.subject.keywordPlus | TERM | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ADULTS | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0140673618321962?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.